• Research Tree
  • Features
  • Pricing
  • Events
  • Reg.News
  • Short Interest
  • Explore Content
    • Explore

      • Providers
        • Providers

          • Free/Commissioned
          • High Net Worth Offering
          • Institutional Offering

          Free/Commissioned

          Research that is free to access for all investors. Companies commission these providers to write research about them.

          View Research

          What is our Main Bundle Offering?

          Brokers who write research on their corporate clients and make it available through our main bundle offering.

          View Research

          What is Institutional?

          Research that is paid for directly by asset managers. Only accessible to institutional investors permissioned for access.

          View Research
      • Regions
        • Regions

          • UK
          • Rest of EMEA
          • N America
          • APAC
          • LatAm
      • Exchanges
        • Exchanges

          • Aquis Apex
          • Australian Securities Exchange
          • Canadian Securities Exchange
          • Euronext Paris
          • London Stock Exchange (domestic)
          • SIX Swiss Exchange
      • Sectors
        • Sector Coverage

          • Building & Construction
          • Discretionary Personal Goods
          • Discretionary Retail
          • Energy
          • Health
          • Investment Trusts
          • Media
          • Resources
          • Technology
      • Small / Large Cap
        • Small / Large Cap

          • UK100
          • UK250
          • UK Smallcap
          • UK Other Main Markets
          • Other
  • Login
  • Sign Up
LIVE

Event in Progress:

Join Here ×

working
  • 12 Oct 2021

R&D update: RXC004 and RXC007 in the spotlight 12 October 2021

  • Trinity Delta
    • Franc Gregori | Lala Gregorek

    • 2 pages


 

▪ Redx Pharma’s virtual R&D event focussed on its two lead wholly owned assets: RXC004, a porcupine inhibitor shortly set to start its first Phase II trial in genetically selected Wnt-ligand driven cancers, and RXC007, a ROCK2 inhibitor that, following promising initial Phase I data, is expected to enter Phase II studies in idiopathic pulmonary fibrosis in 2022. Building on our September 2021 Update which covered these assets, we highlight new or relevant information emerging from the management and key opinion leader presentations from Prof Scott Kopetz (MD Anderson), Prof Gisli Jenkins (Imperial College London), and Prof Toby Maher (Keck Medicine, USC LA). ▪ Effective targeting of the Wnt pathway has been a clinical goal in many solid tumours, notably mCRC (metastatic colorectal cancer) where it plays a critical role in aggressive disease. mCRC outcomes remain very poor, with median survival of 30 months and five-year survival of 12%. MSS mCRC has an even worse prognosis, and anti-PD-1 checkpoint inhibitors have not shown any monotherapy efficacy. In Q421 RXC004 will begin a Phase II monotherapy programme in genetically selected MSS mCRC and pancreatic cancers, and in biliary tract cancer. A CPI-combination (nivolumab) arm in MSS mCRC will start in H122. Success here would not simply address a genetically specified tumour population but could help unlock the potential of CPIs in mCRC. ▪ RXC007 is a highly specific ROCK2 inhibitor that targets a nodal point in the fibrosis pathways. Historically addressing ROCK without encountering safety issues has proven difficult. Kadmon’s Rezurock (belumosudil) is the first and only approved ROCK2 inhibitor, for cGvHD, which established a regulatory pathway. Early RXC007 Phase I data following a single dose of 2mg through to 40mg has confirmed preclinical pharmacokinetics, with no adverse effects. Although already at the predicted biologically relevant doses, further escalations are continuing. Full Phase I data are expected in H122. ▪ The promise of RXC007 will be explored further in a staged Phase II study in idiopathic pulmonary fibrosis (IPF), a progressive lung condition with a poor prognosis despite two approved products. A Phase IIa safety and tolerability study in IPF with and without standard of care (SoC) will start in 2022 and will inform the Phase IIb dose. The 12-month Phase IIb trial will then evaluate RXC007 plus SoC with forced vital capacity (FVC) lung function as a primary endpoint. If successful here, other fibrotic indications could be explored.

Sign up for free to access

Get access to the latest equity research in real-time from 12 commissioned providers.

Get access to the latest equity research in real-time from 12 commissioned providers.


Get Started
Already a member? Log in here

R&D update: RXC004 and RXC007 in the spotlight 12 October 2021

  • Published: 12 Oct 2021
  • Author: Franc Gregori | Lala Gregorek
  • Pages: 2
  • Trinity Delta


▪ Redx Pharma’s virtual R&D event focussed on its two lead wholly owned assets: RXC004, a porcupine inhibitor shortly set to start its first Phase II trial in genetically selected Wnt-ligand driven cancers, and RXC007, a ROCK2 inhibitor that, following promising initial Phase I data, is expected to enter Phase II studies in idiopathic pulmonary fibrosis in 2022. Building on our September 2021 Update which covered these assets, we highlight new or relevant information emerging from the management and key opinion leader presentations from Prof Scott Kopetz (MD Anderson), Prof Gisli Jenkins (Imperial College London), and Prof Toby Maher (Keck Medicine, USC LA). ▪ Effective targeting of the Wnt pathway has been a clinical goal in many solid tumours, notably mCRC (metastatic colorectal cancer) where it plays a critical role in aggressive disease. mCRC outcomes remain very poor, with median survival of 30 months and five-year survival of 12%. MSS mCRC has an even worse prognosis, and anti-PD-1 checkpoint inhibitors have not shown any monotherapy efficacy. In Q421 RXC004 will begin a Phase II monotherapy programme in genetically selected MSS mCRC and pancreatic cancers, and in biliary tract cancer. A CPI-combination (nivolumab) arm in MSS mCRC will start in H122. Success here would not simply address a genetically specified tumour population but could help unlock the potential of CPIs in mCRC. ▪ RXC007 is a highly specific ROCK2 inhibitor that targets a nodal point in the fibrosis pathways. Historically addressing ROCK without encountering safety issues has proven difficult. Kadmon’s Rezurock (belumosudil) is the first and only approved ROCK2 inhibitor, for cGvHD, which established a regulatory pathway. Early RXC007 Phase I data following a single dose of 2mg through to 40mg has confirmed preclinical pharmacokinetics, with no adverse effects. Although already at the predicted biologically relevant doses, further escalations are continuing. Full Phase I data are expected in H122. ▪ The promise of RXC007 will be explored further in a staged Phase II study in idiopathic pulmonary fibrosis (IPF), a progressive lung condition with a poor prognosis despite two approved products. A Phase IIa safety and tolerability study in IPF with and without standard of care (SoC) will start in 2022 and will inform the Phase IIb dose. The 12-month Phase IIb trial will then evaluate RXC007 plus SoC with forced vital capacity (FVC) lung function as a primary endpoint. If successful here, other fibrotic indications could be explored.

More Content

More Content

Cautious into Q2 — not thereafter

Companies: Camurus (CAMX:STO)Camurus AB (CAMX:OME)

ABG Sundal Collier

AFT Pharmaceuticals:Making progress on growth strategy

Companies: AFT Pharmaceuticals Ltd.

Edison

Actinogen Medical:XanaMIA study enrols 100th patient

Companies: Actinogen Medical Limited

Edison

Newron Pharmaceuticals:Evenamide enters ENIGMA-TRS programme

Companies: Newron Pharmaceuticals S.p.A.

Edison

Cereno Scientific – executive interview

Companies: Cereno Scientific Ab (CRNOB:STO)Cereno Scientific AB Class B (CRNO.B:OME)

Edison
Research Tree
Useful Links
  • Features
  • Pricing
  • RNS/Newswires Feeds
  • Providers Hub
  • Company Hub
  • Stock Pick League
  • Chrome Extension
  • iOS and Android Apps
Account
  • Login
  • Join Now
  • Contact
  • Follow us on Linkedin
  • Follow us on X

© Research Tree 2025

  • Apple Store
  • Play Store
  • Terms of Service
  • Privacy Policy and Statement on Cookies

Research Tree will never share your details with third parties for marketing purposes. Research Tree distributes research documents that have been produced and approved by Financial Conduct Authority (FCA) Authorised & Regulated firms as well as relevant content from non-authorised sources, who are not regulated but the information is in the public domain. For the avoidance of doubt Research Tree is not giving advice, nor has Research Tree validated any of the information.

Research Tree is an Appointed Representative of Sturgeon Ventures which is Authorised and Regulated by the Financial Conduct Authority.

Top
  • Home
  • Features
  • Pricing
  • Event Hub
  • Reg.News
  • Short Interest Tracker
  • Explore Content
    • Regions
      • UK
      • Rest of EMEA
      • N America
      • APAC
      • LatAm
    • Exchanges
      • Aquis Apex
      • Australian Securities Exchange
      • Canadian Securities Exchange
      • Euronext Paris
      • London Stock Exchange (domestic)
      • SIX Swiss Exchange
    • Sectors
      • Automobile Industry
      • Banks
      • Building & Construction
      • Chemicals
      • Discretionary Personal Goods
      • Discretionary Retail
      • Energy
      • ETFs
      • Financial Services
      • Food & Drink
      • Food Production
      • Health
      • Household Goods & DIY
      • Industrial Equipment, Goods & Services
      • Insurance & Reinsurance
      • Investment Trusts
      • Leisure, Tourism & Travel
      • Media
      • Open-ended Funds
      • Other
      • Real Estate
      • Resources
      • Staple Retail
      • Technology
      • Telecoms
      • Utilities
    • Small / Large Cap
      • UK100
      • UK250
      • UK Smallcap
      • UK Other Main Markets
      • Other
    • Private/EIS
      • EIS Single Company
      • EIS/SEIS Funds
      • IHT Products
      • SEIS Single Company
      • VCT Funds
  • Providers
    • Free/Commissioned
      • Acquisdata
      • Actinver
      • Actio Advisors
      • Asset TV
      • Astris Advisory
      • Atrium Research
      • Baden Hill
      • BlytheRay
      • BNP Paribas Exane - Sponsored Research
      • Bondcritic
      • Brand Communications
      • BRR Media
      • Calvine Partners
      • Capital Access Group
      • Capital Link
      • Capital Markets Brokers
      • Cavendish
      • Checkpoint Partners
      • Clear Capital Markets
      • Couloir Capital
      • Doceo
      • Edison
      • Engage Investor
      • Equity Development
      • eResearch
      • First Equity
      • Five Minute Pitch TV
      • focusIR
      • Fundamental Research Corp
      • Galliano’s Latin Notes
      • GBC AG
      • goetzpartners securities Limited
      • Golden Section Capital
      • GreenSome Finance
      • GSBR Research
      • H2 Radnor
      • Hardman & Co
      • Holland Advisors
      • Hypothesis Research
      • InterAxS Global
      • Kepler | Trust Intelligence
      • London Stock Exchange
      • Longspur Clean Energy
      • Mello Events
      • Messari Research
      • Nippon Investment Bespoke Research UK
      • NuWays
      • OAK Securities
      • Oberon Capital
      • Optimo Capital
      • Panmure Liberum
      • Paul Scott
      • Peel Hunt
      • PIWORLD / Progressive
      • Proactive
      • Progressive Equity Research
      • Quantum Research Group
      • QuotedData
      • Research Dynamics
      • Research Tree
      • Resolve Research
      • SEAL Advisors Ltd
      • ShareSoc
      • Shore Capital
      • Sidoti & Company
      • Small Cap Consumer Research LLC
      • StockBox
      • Tennyson Securities
      • The AIC
      • The Business Magazine Group
      • The Edge Group
      • The Life Sciences Division
      • Trinity Delta
      • Turner Pope Investments
      • UK Investor Group
      • ValueTrack
      • Vox Markets
      • VRS International S.A. - Valuation & Research Specialists (VRS)
      • VSA Capital
      • Winterflood Securities
      • Yaru Investments
      • Yellowstone Advisory
      • Zacks Small Cap Research
      • Zeus Capital
    • High Net Worth Offering
      • Fox-Davies Capital
      • ABG Sundal Collier
      • ACF Equity Research
      • Align Research
      • Allenby Capital
      • AlphaValue
      • Alternative Resource Capital
      • Arctic Securities
      • Arden Partners
      • Auctus Advisors
      • Baptista Research
      • BNP Paribas Exane - Sponsored Research
      • Canaccord Genuity
      • Cavendish
      • Couloir Capital
      • Degroof Petercam
      • Dowgate Capital
      • First Berlin
      • First Equity
      • First Sentinel
      • Greenwood Capital Partners
      • Hannam & Partners
      • Hybridan
      • Kemeny Capital
      • Longspur Clean Energy
      • Louis Capital
      • Magnitogorsk Iron and steel works
      • Medley Global Advisors
      • Northland Capital Partners
      • OAK Securities
      • Oberon Capital
      • Panmure Liberum
      • QuotedData Professional
      • Shard Capital
      • ShareSoc
      • Shore Capital
      • Singer Capital Markets
      • SP Angel
      • Stanford Capital Partners
      • Stifel FirstEnergy
      • Stockdale Securities
      • Tamesis Partners
      • Tennyson Securities
      • The Life Sciences Division
      • Turner Pope Investments
      • VSA Capital
      • Whitman Howard
      • Yellowstone Advisory
      • Zeus Capital
    • Institutional Offering
      • Fox-Davies Capital
      • ABG Sundal Collier
      • ACF Equity Research
      • Acquisdata
      • Allenby Capital
      • Alternative Resource Capital
      • Arctic Securities
      • Arden Partners
      • Auctus Advisors
      • BNP Paribas Exane
      • Bondcritic
      • Canaccord Genuity
      • Capital Access Group
      • Capital Link
      • Cavendish
      • Couloir Capital
      • Degroof Petercam
      • Dowgate Capital
      • Edison
      • First Berlin
      • First Equity
      • First Sentinel
      • Five Minute Pitch TV
      • Fundamental Research Corp
      • Galliano’s Latin Notes
      • GBC AG
      • Golden Section Capital
      • Goodbody
      • Greenwood Capital Partners
      • Hannam & Partners
      • Holland Advisors
      • Hybridan
      • InterAxS Global
      • Investec Bank
      • Kepler | Trust Intelligence
      • Numis
      • NuWays
      • OAK Securities
      • Oberon Capital
      • Panmure Liberum
      • Peel Hunt
      • QuotedData
      • QuotedData Professional
      • Research Dynamics
      • Research Tree
      • Shard Capital
      • Shore Capital
      • Sidoti & Company
      • Singer Capital Markets
      • Small Cap Consumer Research LLC
      • SP Angel
      • Stanford Capital Partners
      • Stifel
      • StockBox
      • Tamesis Partners
      • Tennyson Securities
      • The AIC
      • The Business Magazine Group
      • The Life Sciences Division
      • ValueTrack
      • Velocity Trade
      • VSA Capital
      • Winterflood Securities
      • Zacks Small Cap Research
      • Zeus Capital
  • Contact
  • Sign Up
  • Sign In